BioBridgeXAll companies

Metagenomi Therapeutics, Inc.

Biotechnology company · Emeryville, California, United States · Nasdaq: MGX

Metagenomi Therapeutics, Inc. is a biotechnology company headquartered in Emeryville, California, United States. Its earliest recorded incorporation is in 2018. Its shares trade on Nasdaq under the ticker MGX. It has reported private securities offerings to the US SEC, most recently $96 million sold in a notice filed in 2023.

Profile compiled from public records. Is this your company? Request a correction or update

Metagenomi Therapeutics at a glance

Typebiotechnology company
HeadquartersEmeryville, California, United States
Earliest incorporation on record2018
Stock listingNasdaq: MGX
SEC industryBiological Products, (No Diagnostic Substances)
SEC CIK1785279

What does Metagenomi Therapeutics do?

Private fundraising reported to the SEC

3 Form D notices; the most recent reported $95.8 million sold (2023).

Frequently asked questions about Metagenomi Therapeutics

Where is Metagenomi Therapeutics headquartered?

Metagenomi Therapeutics, Inc. is headquartered in Emeryville, California, United States.

What does Metagenomi Therapeutics do?

Metagenomi Therapeutics, Inc. is a biotechnology company. Its SEC industry classification is Biological Products, (No Diagnostic Substances).

Is Metagenomi Therapeutics a public company?

Yes. Metagenomi Therapeutics, Inc. trades on Nasdaq under the ticker MGX.

When was Metagenomi Therapeutics founded?

The earliest incorporation on record for Metagenomi Therapeutics, Inc. is in 2018, according to public company registers.

Similar companies

Need a CRO or CDMO for your next study?

Compare transparent quotes from research and manufacturing partners, then contract once. Free for buyers.

Compare quotes

Last updated 2026-09-25. Data licences